Although a severe comorbidity score is associated with an increased likelihood of G-CSF use either prophylactically or reactively in patients undergoing intermediate- or low-risk chemotherapy regimens [7], a study among older breast cancer patients with a comorbidity score of 3 or greater showed less likelihood of receiving a G-CSF as primary prophylaxis [36]. The gene discussed is CSF3; the disease is breast cancer.